Figure 3

<b>Figure 3 | Activation of astro-hM3Dq signaling increases c-Fos expression.</b> a, Experimental timeline for astro-hM3Dq control and positive mice, receiving clozapine N-oxide (CNO) (1 mg/kg i.p.). b, Representative immunostaining image (10x) of astro-hM3Dq-positive mice (n=5) showing Hoechst (blue), Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) that are tagged with a hemagglutinin (HA)-epitope (green), glial fibrillary acidic protein (GFAP, red), and c-Fos (magenta). c, Representative immunostaining image (10x) of control mice (n=4) showing Hoechst (blue), DREADD-HA epitope (green), GFAP (red), and c-Fos (magenta). d, Representative astro-hM3Dq positive immunostaining image (40x) in the hippocampus indicating Hoechst, HA, GFAP, c-Fos, and the merged image. e, Representative astro-hM3Dq positive immunostaining image (40x) in the thalamus indicating Hoechst, HA, GFAP, c-FOS and the merged image. f, Representative control immunostaining image (40x) in the hippocampus indicating Hoechst, HA, GFAP, c-Fos, and the merged image. g, Representative control immunostaining image (40x) in the thalamus indicating Hoechst, HA, GFAP, c-Fos, and the merged image. Scale bars: b, c = 200 ; d-g = 50 . h-k, Percent area of c-Fos expression in h, cortex, i, hippocampus, j, thalamus, and k, hypothalamus. Each symbol on the graph represents an individual animal. Data are expressed as mean SEM. Unpaired, two-tailed Student t-test. ** &lt;0.001, **** &lt;0.0001.